Full Press Release Details
Spruce Biosciences to Participate in the B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc.(Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at the B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit, in a fireside chat hosted by Madison El-Saadi, Ph.D., Healthcare Research Analyst.
The B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit will take place on July 16, 2026, at the InterContinental Boston hotel in Boston, MA.
Participation in the summit is by invitation only. Investors interested in scheduling an in-person meeting with the Spruce management team should contact their B. Riley Securities representative or emailhealthcareevents@brileysecurities.com.
About Spruce Biosciences
Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need. Spruce’s lead product candidate, tralesinidase alfa enzyme replacement therapy (TA-ERT), is in late-stage development for the treatment of mucopolysaccharidoses type IIIB (MPS IIIB), or Sanfilippo Syndrome Type B, a devastating pediatric neurodegenerative disorder for which there are no FDA-approved therapies. TA-ERT has received Breakthrough Therapy Designation, Rare Pediatric Disease Designation, Fast Track Designation and Orphan Drug Designation from the FDA, as well as Orphan Drug Designation in the European Union. To learn more, visitwww.sprucebio.comand follow us onX,LinkedIn,FacebookandYouTube.
MediaCarolyn HawleyInizio Evoke CommsCarolyn.Hawley@inizioevoke.commedia@sprucebio.comInvestorsMonique KosseGilmartin GroupMonique@GilmartinIR.cominvestors@sprucebio.com